Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 200 pages

Showing 151 - 200


lymphoma

Para-Aortic Lymph Node Radiation Increases Risk of Diabetes in Hodgkin Lymphoma Survivors

Abdominal irradiation for childhood cancer has been associated with increased risk of diabetes. In a Dutch study reported in the Journal of Clinical Oncology, van Nimwegen and colleagues assessed the relationship between infradiaphragm radiotherapy and risk of diabetes in long-term survivors of...

lymphoma

Anti-CD19 CAR T-Cell Treatment Effective in Chemotherapy-Refractory B-Cell Malignancies

In a study reported in the Journal of Clinical Oncology, Kochenderfer et al found that single infusions of autologous T cells expressing an anti-CD19 chimeric antigen receptor (CAR) produced responses in nearly all patients with chemotherapy-refractory CD19-positive B-cell malignancies, including...

lymphoma

No Significant Difference in Time to Treatment Failure With Rituximab Retreatment vs Maintenance in Low-Tumor-Burden Follicular Lymphoma

Maintenance rituximab (Rituxan) has been shown to improve progression-free survival vs observation in low-tumor-burden follicular lymphoma. In the Eastern Cooperative Oncology Group (ECOG) E4402 Trial (RESORT), reported in the Journal of Clinical Oncology, Kahl et al found no significant difference ...

lymphoma

Adding Lenalidomide to R-CHOP Appears to Overcome Negative Prognostic Impact of the Non-Germinal Center B-Cell Phenotype in DLBCL

A phase II study reported in the Journal of Clinical Oncology by Nowakowski et al indicates that the addition of lenalidomide (Revlimid) to R-CHOP (rituximab [Rituxan] plus cyclophosphamide, doxorubicin, vincristine, and prednisone)—a regimen known as R2CHOP—overcomes the negative...

lymphoma

Vitamin D Deficiency Worsens Response to Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

In a study reported in the Journal of Clinical Oncology, Bittenbring et al found that vitamin D deficiency was associated with poorer outcome in older patients receiving R-CHOP (rituximab [Rituxan] plus cyclophosphamide, doxorubicin, vincristine, and prednisone) for diffuse large B-cell lymphoma...

lymphoma

Brentuximab Vedotin Shows First-Line Activity in Phase I Study in CD30-Positive Peripheral T-Cell Lymphoma

In a phase I study reported in the Journal of Clinical Oncology, Fanale et al found that brentuximab vedotin (Adcetris)—a conjugate of antibody specific for CD30 and a microtubule-disrupting chemotherapy agent—exhibited high activity when combined sequentially with CHOP...

lymphoma

Updated Recommendations for Evaluation, Staging, and Response Assessment for Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Updated recommendations (the Lugano Classification) for initial evaluation, staging, and assessment of response in patients with Hodgkin lymphoma and non-Hodgkin lymphoma (NHL) have been presented in the Journal of Clinical Oncology by Cheson et al. The recommendations are the result of two...

lymphoma

ICML Imaging Working Group Issues Updated Guidelines on PET-CT for Staging and Response Assessment for FDG-Avid Lymphomas

Barrington et al in the International Conference on Malignant Lymphomas Imaging Working Group have presented updated consensus guidelines on 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)-computed tomography (CT) for staging and response assessment for FDG-avid lymphomas. The...

lymphoma

Negative PET/CT After One Cycle of Chemotherapy Strongly Predicts Favorable Outcome in Hodgkin Lymphoma

Negative 18F–fluorodeoxyglucose positron-emission tomography (PET)/computed tomography (CT) after two cycles of chemotherapy (PET2) has been shown to be associated with favorable prognosis in Hodgkin lymphoma. In a prospective study reported in the Journal of Clinical Oncology, Hutchings et...

lymphoma

High Prevalence of and Shorter Survival With MYD88 Mutation in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type

The activating mutation MYD88 L265P has been reported in approximately two-thirds of cases of primary cutaneous diffuse large B-cell lymphoma, leg-type. In a French retrospective analysis reported in JAMA Dermatology, Pham-Ledard et al confirmed the high prevalence of the mutation and documented...

lymphoma

Phase Ib Study Shows Activity of Ibrutinib Plus R-CHOP in First-Line Treatment of CD20-Positive B-Cell Non-Hodgkin Lymphoma

The oral Bruton's tyrosine kinase inhibitor ibrutinib (Imbruvica) has shown activity in relapsed and refractory B-cell malignancies. In a phase Ib trial reported in The Lancet Oncology, Younes et al identified no maximum tolerated dose of ibrutinib when combined with R-CHOP (rituximab [Rituxan],...

lymphoma

No Apparent Benefit of Rituximab After Lymphoma-Directed Conditioning and Allogeneic Stem Cell Transplantation for Relapsed/Refractory Aggressive NHL

In an open-label phase II trial reported in The Lancet Oncology, Glass et al examined the strategy of adding rituximab (Rituxan) to standard prophylaxis for graft-vs-host disease after allogeneic stem cell transplantation in relapsed or refractory aggressive non-Hodgkin lymphoma. Rituximab did not...

lymphoma

Lenalidomide Plus R-CHOP21 Highly Active in Elderly Patients With Untreated Diffuse Large B-Cell Lymphoma

Lenalidomide (Revlimid) is active in relapsed or refractory aggressive B-cell lymphomas. In a European phase II trial (REAL07) reported in The Lancet Oncology, Vitolo et al examined the addition of lenalidomide to rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisolone...

lymphoma

Diffuse Erythema Predicts Complete Remission of Skin Disease With Alemtuzumab in Leukemic Cutaneous T-Cell Lymphoma

As reported in a research letter in JAMA Dermatology, Watanabe et al found that diffuse erythema at presentation in patients with leukemic T-cell lymphoma was associated with better response to low-dose alemtuzumab (Campath) compared with patients presenting with preexisting plaques or tumors....

lymphoma

PET Plus CT-Assessed Relative Tumor Size Reduction After Chemotherapy Identifies High Risk for Progression and Relapse in Advanced Hodgkin Lymphoma

Positive positron-emission tomography (PET) scans have low positive predictive value after chemotherapy in patients with Hodgkin lymphoma. In a study reported in the Journal of Clinical Oncology, Kobe et al assessed whether use of pretreatment and post-treatment computed tomography (CT) could...

issues in oncology
lymphoma

High t(14;18) Translocation Frequency Predicts Follicular Lymphoma up to 15 Years Later

The t(14;18) translocation is a hallmark and critical event in the development of follicular lymphoma, but it is also detectable in otherwise healthy persons, and its relationship to progression to disease is unclear. In a study reported in the Journal of Clinical Oncology, Roulland et al found...

lymphoma

Validation of Mantle Cell Lymphoma International Prognostic Index in European Mantle Cell Lymphoma Network Trials

The Mantle Cell Lymphoma International Prognostic Index (MIPI) was developed in 2008 as the first prognostic stratification system specific for mantle cell lymphoma (MCL). In a study reported in the Journal of Clinical Oncology, Hoster et al confirmed the validity of MIPI in a cohort of two...

lymphoma

Omitting Radiotherapy in Early PET-Negative Stage I/II Hodgkin Lymphoma Is Associated With Increased Risk of Early Relapse

The EORTC/LYSA/FIL Intergroup H10 trial assessed whether omitting involved-node radiotherapy would affect progression-free survival in patients with negative early positron-emission tomography (PET) scans after two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) compared with...

lymphoma

Rituximab Maintenance Delays Need for Subsequent Treatment vs Watchful Waiting in Asymptomatic Nonbulky Follicular Lymphoma

In an open-label phase III trial reported by Ardeshna et al in The Lancet Oncology, rituximab (Rituxan) induction plus maintenance was found to delay the need for subsequent therapy and improve elements of quality of life vs watchful waiting in patients with advanced asymptomatic nonbulky...

lymphoma

Standard 24 Gy More Effective Than 4 Gy in Radiotherapy for Indolent Lymphoma

Follicular lymphoma has been found to respond to radiotherapy doses as low as 4 Gy. In the phase III FORT trial reported in The Lancet Oncology, Hoskin et al compared radiotherapy with 4 Gy in two fractions vs 24 Gy in 12 fractions in patients with indolent lymphoma, finding that the 24-Gy regimen...

lymphoma

Event-Free Survival at 24 Months Can Serve as Endpoint for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

In a study reported in the Journal of Clinical Oncology, Maurer et al found that patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy who achieve event-free survival at 24 months have overall survival that does not differ significantly from that in the general...

lymphoma

Rituximab Active in Nodular Lymphocyte–Predominant Hodgkin Lymphoma

Mature results of a phase II study reported in the Journal of Clinical Oncology by Advani et al indicate that rituximab (Rituxan) is active in nodular lymphocyte–predominant Hodgkin lymphoma, which is characterized by expression of CD20 by malignant cells. Most patients relapsed, but durable...

lymphoma

Radiotherapy for Bulky Disease Added to R-CHOP Improves Outcome in Elderly Patients With Aggressive B-Cell Lymphoma

In an analysis reported in the Journal of Clinical Oncology, Held et al studied elderly patients with aggressive B-cell non-Hodgkin lymphoma and bulky disease in the most effective treatment arm of the RICOVER-60 trial, which included radiotherapy. The investigators compared outcomes ...

lymphoma

Crizotinib Produces Durable Responses in Small Study of Patients With Advanced, Chemoresistant ALK-Positive Lymphoma

In a brief communication in the Journal of the National Cancer Institute, Passerini et al described compassionate use experience with the ALK inhibitor crizotinib (Xalkori) in a group of patients with chemoresistant advanced ALK-positive lymphoma. Response was observed in 10 of 11 patients, and...

lymphoma

PI3K-Delta Inhibitor Idelalisib Produces High Response Rates in Relapsed Indolent Lymphoma

Phosphatidylinositol 3-kinase (PI3K)-delta mediates B-cell receptor signaling and microenvironment support signals that promote the growth and survival of malignant B lymphocytes. In a phase II study reported in The New England Journal of Medicine, Gopal et al found that the PI3K-delta inhibitor...

lymphoma

No Survival Difference for Autologous vs Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Chemotherapy-Sensitive Mantle Cell Lymphoma

In an analysis reported in the Journal of Clinical Oncology, Fenske et al compared outcomes with early or late autologous vs reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in a population of patients with chemotherapy-sensitive mantle cell lymphoma. They found no...

lymphoma

Sustained Complete Responses With Novel Immunotherapy in Lymphoma

Approximately 40% of patients with Hodgkin or non-Hodgkin lymphoma have tumor cells that express the type II latency Epstein-Barr virus (EBV) antigens latent membrane protein 1 (LMP1) and LMP2. T cells specific for these antigens are present in low levels and may be rendered nonreactive by the...

lymphoma

Anti–PD-1 Antibody Pidilizumab Plus Rituximab Shows High Activity in Relapsed Follicular Lymphoma

Antitumor immune responses may be inhibited by immune checkpoints in the tumor microenvironment including effects of PD-1 (programmed cell death 1), a co-inhibitory receptor on tumor T cells that impairs T-cell function. In a phase II study reported in The Lancet Oncology, Westin et al assessed the ...

lymphoma

Fractionated 90Y-Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rate in Initial Therapy for Follicular Lymphoma

In a phase II trial reported in the Journal of Clinical Oncology, Illidge et al evaluated radioimmunotherapy with fractionated 90Y-ibritumomab tiuxetan (Zevalin) as initial treatment in patients with mostly advanced follicular lymphoma. The treatment was well tolerated, with manageable...

lymphoma

Brentuximab Vedotin Plus ABVD or AVD Is Highly Active in Newly Diagnosed Hodgkin Lymphoma

Brentuximab vedotin (Adcetris) is active in patients with relapsed/refractory Hodgkin’s lymphoma. In a phase I study reported in The Lancet Oncology, Anas Younes, MD, of Memorial Sloan-Kettering Cancer Center (formerly of The University of Texas MD Anderson Cancer Center), and colleagues...

lymphoma
issues in oncology

STAT3 Activation Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP

In a study reported in the Journal of Clinical Oncology, Xin Huang, PhD, of the National Clinical Research Center of Cancer in Tianjin, and colleagues investigated whether STAT3 activation can identify patients with diffuse large B-cell lymphoma treated with R-CHOP (rituximab [Rituxan] plus...

lymphoma

Prognostic Score Predicts Overall Survival in Older Patients With Hodgkin Lymphoma by Second-Line Treatment Strategy

In a study reported in the Journal of Clinical Oncology, Boris Böll, MD, of University Hospital Cologne, and colleagues analyzed second-line treatment and survival in older patients with relapsed/refractory Hodgkin lymphoma in German Hodgkin Study Group first-line studies. Use of a...

lymphoma

Early Autologous Transplantation Improves Progression-Free Survival in Aggressive Non-Hodgkin Lymphoma

The strategy of autologous stem cell transplantation as consolidation in high-intermediate– or high-risk diffuse aggressive non-Hodgkin lymphoma (NHL) has not been specifically examined in the rituximab (Rituxan) era. In a phase III trial (Southwest Oncology Group 9704) reported in The New...

lymphoma

Promising Outcomes With R-MPV Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma

In a phase II trial reported in the Journal of Clinical Oncology, Patrick G. Morris, MD, of Memorial Sloan-Kettering Cancer Center, and colleagues assessed the efficacy of rituximab (Rituxan), methotrexate, procarbazine (Matulane), and vincristine (R-MPV) followed by consolidation reduced-dose ...

lymphoma

Addition of Rituximab Does Not Improve Outcome in Aggressive B-Cell Lymphoma With Skeletal Involvement, but Radiotherapy Benefit Found

In a retrospective analysis of German High-Grade Non-Hodgkin Lymphoma Study Group trials reported in Journal of Clinical Oncology, Gerhard Held, MD, of Saarland University Medical School in Homburg, and colleagues assessed the impact of rituximab (Rituxan) and radiotherapy on outcome in patients...

lymphoma

For Pregnant Women With Lymphoma, Standard Combination Chemotherapy Given After First Trimester Associated With Few Complications

Lymphoma is the fourth most frequent cancer to occur during pregnancy. In a multicenter retrospective analysis reported in Journal of Clinical Oncology, Andrew M. Evens, DO, MSc, of Tufts University Medical School, and colleagues examined treatment, complications, and outcomes for Hodgkin lymphoma...

lymphoma

Phase II Study Shows Activity of Selective Aurora A Kinase Inhibitor Alisertib in Relapsed/Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphoma

Aurora A kinase is overexpressed in aggressive lymphomas and may correlate with more histologically aggressive forms of disease. In a phase II study reported in Journal of Clinical Oncology, Jonathan W. Friedberg, MD, of University of Rochester Wilmot Cancer Center, and colleagues assessed the...

lymphoma

Phase II Study Shows Durable Effect of Lenalidomide in Relapsed/Refractory Mantle Cell Lymphoma

In a phase II study (MCL-001, EMERGE) reported in Journal of Clinical Oncology, Andre Goy, MD, of Hackensack University Medical Center, and colleagues evaluated the use of single-agent lenalidomide (Revlimid) in bortezomib (Velcade)-treated patients who had relapsed/refractory mantle cell lymphoma. ...

lymphoma

Study Compares Rituximab Maintenance to Observation After First-Line Treatment in Older Patients With Advanced Follicular Lymphoma

In an Italian study reported in the Journal of Clinical Oncology by Umberto Vitolo, MD, and colleagues in the Fondazione Italiana Linfomi, treatment-naive patients aged > 60 years with advanced follicular lymphoma were randomized to rituximab [Rituxan] maintenance or observation after brief ...

lymphoma
survivorship

Decreased White Matter Integrity and Neuropsychological Function Seen Decades After Cranial Radiotherapy for Pediatric Lymphoid Malignancies

CNS-directed chemotherapy and cranial radiation therapy for childhood acute lymphoblastic leukemia or lymphoma have neurotoxic effects. In a study reported in Journal of Clinical Oncology, Ilse Schuitema, MSc, of Leiden University, The Netherlands, and colleagues evaluated white matter changes ...

lymphoma

Meta-Analysis Indicates BEACOPPescalated Is Superior in Advanced Hodgkin Lymphoma

Studies evaluating two standards of care in adults with advanced Hodgkin lymphoma—ie, increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine (Matulane), and prednisone (BEACOPPescalated) and doxorubicin, bleomycin, vinblastine, and dacarbazine...

lymphoma

Benefit Seen with Both Autologous and Allogeneic Hematopoietic Cell Transplantation in T-cell Non-Hodgkin Lymphoma

In a report in Journal of Clinical Oncology, Sonali M. Smith, MD, of University of Chicago Hospitals, and colleagues analyzed outcomes in a large cohort of autologous or allogeneic hematopoietic cell transplantation recipients with the most common T-cell non-Hodgkin lymphoma histologies. Their ...

lymphoma
issues in oncology

Molecular Profiling Improves Classification of Nodal Peripheral T-cell Lymphomas

The differential diagnosis of the most common peripheral T-cell lymphoma subtypes is difficult. In a phase III diagnostic accuracy study reported in Journal of Clinical Oncology, Pier Paolo Piccaluga, MD, PhD, of the University of Bologna, and colleagues in the European T-cell Lymphoma Study Group...

lymphoma

Obinutuzumab Shows Activity in Relapsed/Refractory Diffuse Large B-cell Lymphoma or Mantle Cell Lymphoma and Indolent Non-Hodgkin Lymphoma

Obinutuzumab is a type II, glycoengineered, humanized anti-CD20 monoclonal antibody. In the phase II GAUGUIN studies reported in Journal of Clinical Oncology by Franck Andre Morschhauser, MD, PhD of Centre Hospitalier Régional Universitaire de Lille and Gilles A. Salles, MD, PhD, of Hospices ...

lymphoma

Lugano 2013: BCL2 Overexpression and Non–Germinal Center B-cell–like Subtype Predict Poorer Survival in Diffuse Large B-cell Lymphoma

In studies to identify prognostic factors in diffuse large B-cell lymphomas, Thierry J. Molina, MD, PhD, of Paris Descartes University, and colleagues assessed expression of MYC, BCL2, MYC/BCL2, IgM, and germinal center B-cell–like and non–germinal center B-cell–like subtypes in a ...

lymphoma

Lugano 2013: Vitamin D Deficiency Associated with Worse Outcome in Elderly Patients with Aggressive B-cell Lymphoma Receiving R-CHOP or CHOP

Vitamin D deficiency recently was shown to be associated with worse outcome in patients with non-Hodgkin lymphoma. To determine whether such an association exists in patients with aggressive B-cell lymphoma, Jörg T. Bittenbring, of Saarland University Medical School, Germany, and colleagues in ...

lymphoma

Lugano 2013: Chlorambucil plus Rituximab Produces Better Event-free and Progression-free Survival in Extranodal Marginal Zone B-cell Lymphoma

The International Extranodal Lymphoma Study Group (IELSG)-19 trial is the largest randomized trial in extranodal marginal zone B-cell lymphoma conducted to date. As reported by Emanuele Zucca, MD, of the Oncology Institute of Southern Switzerland, and colleagues, preliminary final results of the...

lymphoma

Lugano 2013: PET-guided Radiation Therapy Improves Survival in Patients with Advanced Diffuse Large B-cell Lymphoma

Residual masses are often detected on post-therapy computed tomography (CT) scans in patients with diffuse large B-cell lymphoma, and the potential role of consolidative radiation therapy in such cases remains undefined. An analysis of the use of PET-guided radiation therapy presented by Laurie H....

lymphoma

BTK Inhibitor Ibrutinib Produces High Response Rate in Relapsed/Refractory Mantle Cell Lymphoma

Ibrutinib is a first-in-class oral covalent inhibitor of Bruton’s tyrosine kinase (BTK), a mediator of the B-cell receptor signaling pathway implicated in the pathogenesis of B-cell cancers. As reported in The New England Journal of Medicine, Michael L. Wang, MD, of The University...

lymphoma

Follicular Lymphoma Cells Induce Changes in T-cell Gene Expression and Function, Show Prognostic Significance for Survival

It has been shown that CD4 and CD8 tumor-infiltrating lymphocytes in follicular lymphoma have impaired function and suppressed recruitment of critical signaling proteins to the immunologic synapse, and a number of studies have indicated the prognostic importance of the immune microenvironment in...

Advertisement

Advertisement



;
Advertisement